ABT Stock Overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for ABT from our risk checks.
Narratives
BetaNarratives bring a range of perspectives from our community.
Abbott Laboratories Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$105.27 |
| 52 Week High | US$121.64 |
| 52 Week Low | US$89.67 |
| Beta | 0.74 |
| 1 Month Change | -6.97% |
| 3 Month Change | -8.21% |
| 1 Year Change | -4.60% |
| 3 Year Change | -14.76% |
| 5 Year Change | 34.77% |
| Change since IPO | 28,645.72% |
Recent News & Updates
Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15
Recent updates
Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now
Mar 21Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger
Mar 19Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
Feb 27Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon
Feb 08The King Is Back: Abbott Laboratories' Path To >11% Annual Returns
Jan 29The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts
Jan 26Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King
Dec 28Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Dec 27Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio
Dec 03Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?
Nov 29Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market
Nov 26Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?
Nov 01Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up
Oct 24Abbott: A Diversified Health Care Company With Strong Underlying Growth
Oct 20Abbott Laboratories Triumphs Over Challenges: A Tale Of Resilience
Sep 29Abbott Laboratories' (NYSE:ABT) Intrinsic Value Is Potentially 33% Above Its Share Price
Sep 26Abbott Laboratories: Buy This Fairly Valued Dividend King For Consistently Rising Income
Sep 17We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt
Aug 13Abbott: This Dividend King Is Ready For Takeoff
Jul 31Abbott Laboratories Q2 2023 Earnings Preview: Expect Incremental Improvement
Jul 17The Big Trends: New Frontiers in Healthcare
Jul 13
Abbott Laboratories (NYSE:ABT) Is Experiencing Growth In Returns On Capital
Jul 12Calculating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Jun 25Abbott Laboratories: Offers Promising Buying Opportunity (Technical Analysis)
Jun 23Shareholder Returns
| ABT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -5.5% | -4.4% | -3.7% |
| 1Y | -4.6% | -2.8% | 20.2% |
Return vs Industry: ABT underperformed the US Medical Equipment industry which returned -2.8% over the past year.
Return vs Market: ABT underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| ABT volatility | |
|---|---|
| ABT Average Weekly Movement | 2.7% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ABT has not had significant price volatility in the past 3 months.
Volatility Over Time: ABT's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1888 | 114,000 | Robert Ford | www.abbott.com |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Abbott Laboratories Fundamentals Summary
| ABT fundamental statistics | |
|---|---|
| Market cap | US$182.66b |
| Earnings (TTM) | US$5.61b |
| Revenue (TTM) | US$40.33b |
32.6x
P/E Ratio4.5x
P/S RatioIs ABT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABT income statement (TTM) | |
|---|---|
| Revenue | US$40.33b |
| Cost of Revenue | US$18.03b |
| Gross Profit | US$22.29b |
| Other Expenses | US$16.68b |
| Earnings | US$5.61b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.23 |
| Gross Margin | 55.28% |
| Net Profit Margin | 13.91% |
| Debt/Equity Ratio | 40.9% |
How did ABT perform over the long term?
See historical performance and comparison